Synergistic suppression of ovarian cancer by combining NRF2 and GPX4 inhibitors: in vitro and in vivo evidence

Ning Li,Xingmei Jiang,Qingyu Zhang,Yongmei Huang,Jinbin Wei,Haitao Zhang,Hui Luo

DOI: https://doi.org/10.1186/s13048-024-01366-8

2024-02-25

Journal of Ovarian Research

Abstract:Ovarian cancer is a significant challenge in women's health due to the lack of effective screening and diagnostic methods, often leading to late detection and the highest mortality rate among all gynecologic tumors worldwide. Recent research has shown that ovarian cancer has an "iron addiction" phenotype which makes it vulnerable to ferroptosis inducers. We tested the combination of NRF2-targeted inhibitors with GPX4-targeted inhibitors in ovarian cancer through in vitro and in vivo experiment. The data showed that combination treatment effectively suppressed adherent cell growth, inhibited suspended cell spheroid formation, and restrained the ability of spheroid formation in 3D-culture. Mechanistically, the combination induced accumulation of ROS, 4-HNE, as well as activation of caspase-3 which indicates that this combination simultaneously increases cell ferroptosis and apoptosis. Notably, inhibition of GPX4 or NRF2 can suppress ovarian cancer spreading and growth in the peritoneal cavity of mice, while the combination of NRF2 inhibitor ML385 with GPX4 inhibitors showed a significant synergistic effect compared to individual drug treatment in a syngeneic mouse ovarian cancer model. Overall, these findings suggest that combining NRF2 inhibitors with GPX4 inhibitors results in a synergy suppression of ovarian cancer in vitro and in vivo, and maybe a promising therapeutic strategy for the treatment of ovarian cancer.

reproductive biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the development of effective treatment strategies for ovarian cancer. Specifically, the authors explored the potential of inhibiting the growth and metastasis of ovarian cancer cells by using NRF2 inhibitors and GPX4 inhibitors in combination. The paper points out that ovarian cancer has the characteristic of "iron - dependence", which makes it sensitive to drugs that induce ferroptosis. NRF2 and GPX4 are key molecules involved in cellular antioxidant defense, and their activities can affect the sensitivity of cells to ferroptosis. Therefore, by simultaneously inhibiting these two targets, it may be possible to more effectively induce ferroptosis and apoptosis in ovarian cancer cells, thereby achieving better anti - cancer effects.

### Background and Objectives of the Paper
- **Background**: Ovarian cancer is a major challenge to women's health. Due to the lack of effective screening and diagnostic methods, it is often detected at an advanced stage and has become one of the diseases with the highest mortality rate among gynecological tumors. Recent studies have shown that ovarian cancer exhibits an "iron - dependent" phenotype, making it sensitive to ferroptosis inducers.
- **Objectives**: To study the synergistic inhibitory effect of the combined use of NRF2 inhibitors and GPX4 inhibitors on ovarian cancer in vitro and in vivo, and to explore the feasibility of this combined treatment strategy as a new method for ovarian cancer treatment.

### Main Findings
- **In vitro Experiments**:
- The combined treatment significantly inhibited the growth of adherent cells, inhibited the formation of suspended cell spheres, and reduced the sphere - forming ability of cells in 3D culture.
- Mechanistically, the combined treatment induced the accumulation of ROS (reactive oxygen species) and 4 - HNE (4 - hydroxynonenal), as well as the activation of caspase - 3, indicating that this combined treatment simultaneously increased ferroptosis and apoptosis in cells.
- **In vivo Experiments**:
- In an allograft model of ovarian cancer cells implanted intraperitoneally in mice, using GPX4 or NRF2 inhibitors alone could inhibit the spread and growth of ovarian cancer, but the combined use of the NRF2 inhibitor ML385 and GPX4 inhibitors (such as RSL3 or ML210) showed a significant synergistic effect and was more effective than single - drug use.

### Conclusions
- **Conclusion**: The combined use of NRF2 inhibitors and GPX4 inhibitors can effectively inhibit the growth and metastasis of ovarian cancer both in vitro and in vivo, and this combined treatment strategy may be a promising method for treating ovarian cancer.

### Keywords
- Ovarian cancer, NRF2, GPX4, Apoptosis, Ferroptosis

Through these research results, the authors proposed a new strategy for treating ovarian cancer, that is, by simultaneously inhibiting NRF2 and GPX4 to enhance ferroptosis and apoptosis, thereby more effectively inhibiting the growth and metastasis of ovarian cancer. This strategy is expected to provide new ideas and methods for the treatment of ovarian cancer.